AASLD 2024 Nov 15-19 San Diego
 
Carolin Zitzmann1, Ruy M. Ribeiro1, Sergey Izmailyan2, Shannan Lynch2, Keith Pietropaolo2, Arantxa Horga2, Xiao-Jian Zhou2, Janet Hammond2, Alan S. Perelson1 1Theoretical Biology and Biophysics, Los Alamos National Laboratory, NM, United States 2Atea Pharmaceuticals, Inc., Boston, MA, United States
 
EASL2024: Bemnifosbuvir is a potent HCV NS5B inhibitor with a favorable antiviral profile and high resistance barrier/a>
 
AASLD2023: Bemnifosbuvir and ruzasvir are potent HCV DAAs with favorable antiviral profiles against major HCV NS5A and NS5B RAVs supporting use in combination/a>
 
EASL2023: Lead-in Cohort Results From a Phase 2 Study of a Novel 8-week Combination Regimen of Bemnifosbuvir and Ruzasvir in Patients With Chronic Hepatitis C Virus Infection